Science exchange logo white
  • Solutions
      Buyers

      We are making R&D services readily available to every organization that seeks to make scientific impact. Learn More

      Providers

      We are changing the way providers access and engage customers to streamline the sale and delivery of R&D services. Learn More

      Industries Agriscience Animal Health Basic Research Biopharmaceutical Chemicals Consumer Health Food Science Medical Devices
      Reproducibility

      We believe that good experiments can and should be independently replicated and validated. Learn More

  • Resources
    Innovation Blog
    Customer Stories
    Events
    Industry Trends
    News
    Product Updates
    Help Center
  • About
    About
    Our Story
    Leadership
    Partners
    Join the Team
  • Contact
  • Log In Sign Up
  • Get a Demo
  • Pathophysiology and treatment of significant bleeding oesophageal varices.

    Contemp Nurse. 39(2):221-6. doi: 10.5172/conu.2011.221. October 2011. View on PubMed.
  • Authors

    Jin-Moo Lee (Washington University School of Medicine)
  • Abstract

    Acute oesophageal variceal haemorrhage is a major cause of death associated with cirrhotic liver disease. Whilst surgical procedures can decrease the risk of recurrent bleeds, pharmacological aids are often used to treat the cause of the varices portal hypertension. Insertion of a Sengstaken Blakemore tube or Minnesota tube can temporarily halt the haemorrhage by exerting pressure on the varices. This pressure decreases the blood supply to the oesophagus, thereby decreasing the amount of blood lost through a ruptured vessel. The use of these tubes is based on individual hospital policy. Other techniques such as band ligation, are also being introduced for the management of oesophageal varices to decrease haemorrhaging. Once the bleeding has been controlled surgical procedures such as sclerotherapy can attempt to permanently stop the rupture. However, these procedures do not treat the cause of the varices. Adjunctive medications, transplants and shunts attempt to permanently decrease the portal hypertension in order to decrease the risk of recurrent haemorrhage.

Science exchange logo white

  • Facebook
  • Twitter
  • LinkedIn

Solutions

  • Buyers
  • Providers
  • Reproducibility

Industries

  • Agriscience
  • Animal Health
  • Basic Research
  • Biopharmaceutical
  • Chemicals
  • Consumer Health
  • Food Science
  • Medical Devices

Resources

  • Innovation Blog
  • Customer Stories
  • Events
  • Industry Trends
  • News
  • Product Updates

About

  • Our Story
  • Leadership
  • Partners
  • Join the Team

Support

  • Contact Us
  • Help Center
  • Trust
  • Terms of Use
  • Privacy Policy

Copyright © 2021 Science Exchange, Inc. All rights reserved.